1 Min Read
Aug 21 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd
* Says Hong Kong-based unit invested $36.5 million in Kymab Group Limited
Source text in Chinese:goo.gl/2D7r9G
Further company coverage: (Beijing Headline News)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.